Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Meningitis epidemic threat in West Africa, but few vaccines

07 August 2015, 21:32

Lagos - International health officials are scrambling, without much success, to find meningitis C vaccines as an outbreak of the child-killing disease threatens to balloon into an epidemic.

The first large-scale outbreak of the C strain in decades has this year killed 800 of 12,000 infected people in Nigeria and in neighboring Niger, according to the World Health Organization.

Also read: President Buhari announces weapons production plan

In 2013 and 2014, deaths numbered 128 out of 2,046 people who fell ill, WHO said, indicating the infection rate has soared and could grow much higher in 2016.

"We've never seen this before with meningitis C," William A. Perea, coordinator of WHO's Control of Epidemic Diseases Unit, said of the resurgence of the strain.

The bacterial infection mostly targets children, inflames the brain and spinal cord and kills half those infected if left untreated. Survivors can suffer brain damage, deafness, constant fatigue and neurological and emotional difficulties.

West Africa's biggest epidemic, in 1996, hit four countries, infected a quarter million people and killed 25,000. It was caused predominantly by meningitis A.

Since 2010, the meningitis A conjugate vaccine used across 15 sub-Saharan countries in the "meningitis belt" stretching from Senegal in the west to Ethiopia in the east has reduced infection rates. But it does not protect against the equally deadly C strain.

WHO, and partners including Doctors Without Borders, say they want to build a 5 million-dose stockpile before next year's meningitis season, which runs from January to June during the dry hot months that force people indoors and enable transmission.

While the Indian-manufactured meningitis A vaccine costs around 60 cents, the conjugate vaccine for meningitis C used in the United States costs $30 to $100 a dose. Two doses for babies provide 10 years' protection.

A much cheaper polysaccharide vaccine, produced for travelers, likely will be used as a stop-gap in West Africa. But that vaccine doesn't work for children under 2 and lasts only around two years.

At the start of the last meningitis season in January, only 200,000 meningitis C doses were available for the region, according to Myriam Henkens, international medical coordinator of Doctors Without Borders. By end of the season, in June, international agencies had sourced 1.6 million.

This month, WHO urged manufacturers to increase production. "The first round of discussions, (manufacturers) said no, we just can't produce any more," said Perea.

Major manufacturer Sanofi Pasteur has halted production to upgrade facilities and cannot restart until year's end, according to one of the French-based company's vice presidents, Michael Watson. He said they are one of only four global vaccine producers.

"You can't just turn on the tap," said Watson.

Health leaders have repeatedly asked the government to reopen a vaccine lab which once produced millions of vaccines for yellow fever, rabies and smallpox.

With a domestic market of 170 million people, "in Nigeria it makes a lot of sense," Watson said. "They have a population that justifies it."

In the late 1970s, Nigeria's laboratory made millions of smallpox vaccines that helped eradicate the disease regionally, according to Felix Nwabueze, who was a quality control officer. The lab fell into disrepair under the neglect of corrupt government officials.

"It would be more cost-effective if vaccines were produced in country, and would create employment," said Godswill Okara, former head of the Association of Medical Laboratory Scientists.

Abdulsalami Nasidi, who headed the lab in the 1980s and now is director of Nigeria's Center for Disease Control, fears the potential fatalities if a vaccine shortage and meningitis epidemic collide.

"But we are worried about the paucity not just of the meningitis C vaccine but other vaccines," he added. "Maybe this will teach us a lesson, to really address the local manufacturing issue."

- AP


Read News24’s Comments Policy

Comment on this story
1 comment
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...